Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Lymphoid 1

Conditions

Multiple Myeloma 6Recurrence 4Myelodysplastic Syndromes 4Lymphoma, Non-Hodgkin 4Leukemia, Myeloid, Acute 4Breast Neoplasms 4Prostatic Neoplasms 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Neoplasms 3Pancreatic Neoplasms 2Neoplasm Metastasis 2Lymphoma, T-Cell, Cutaneous 2Lymphoma, Large B-Cell, Diffuse 2Leukemia, Myelogenous, Chronic, BCR-ABL Positive 2Leukemia, Lymphocytic, Chronic, B-Cell 2Leukemia 2Hodgkin Disease 2Hematologic Neoplasms 2Glioma 2Diffuse Intrinsic Pontine Glioma 2Carcinoma, Hepatocellular 2Brain Neoplasms 2Blast Crisis 2Thrombocytosis 1Stomach Neoplasms 1Somatostatinoma 1Solid Tumors 1Small Cell Lung Carcinoma 1Sezary Syndrome 1Rhabdoid Tumor 1

Interventions

Filgrastim 8Cyclophosphamide 8Cyclosporine 7fludarabine phosphate 6Antilymphocyte Serum 6Rituximab 5Radiotherapy 5Peripheral Blood Stem Cell Transplantation 5Mycophenolic Acid 5Methotrexate 5Cord Blood Stem Cell Transplantation 5Etoposide 4Busulfan 4Whole-Body Irradiation 3Methylprednisolone 3Melphalan 3Vincristine 2Tacrolimus 2Ifosfamide 2Granulocyte Colony-Stimulating Factor 2Doxorubicin 2Cytarabine 2Carboplatin 2Amplified Fragment Length Polymorphism Analysis 2venetoclax 1pegfilgrastim 1obatoclax 1ibritumomab tiuxetan 1fludarabine 1etoposide phosphate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Dendritic Cell Sarcoma, Interdigitating × Panobinostat × Clear all
NCT01282476 2017-05-09

Panobinostat With Rituximab for Relapsed/Refractory Diffuse Large B Cell Lymphoma

Massachusetts General Hospital

Phase 2 Terminated
18 enrolled 20 charts
LymphoidSarcoma

Lymphoma, Lymphoma, Large B-Cell, Diffuse, Dendritic Cell Sarcoma, Interdigitating

Data powered by HemOnc (CC BY 4.0) Colophon âš¡